Modality
Degrader
MOA
ALKi
Target
IL-23
Pathway
RAS/MAPK
Celiac
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
~May 2019
→ ~Aug 2020
Phase 3
Nov 2020
→ Apr 2029
Phase 3Current
NCT07417928
716 pts·Celiac
2020-11→2029-04·Terminated
716 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-223.1y awayPh3 Readout· Celiac
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P3
Termina…
Catalysts
Ph3 Readout
2029-04-22 · 3.1y away
Celiac
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07417928 | Phase 3 | Celiac | Terminated | 716 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Tezecilimab | Regeneron | Approved | IL-23 |